Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Principal Investigator

Frances Valdes

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20220204
National Clinical Trials Identifier NCT05159778

Clinical Trial Summary

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall
Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in
patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior
hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent
chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level
(ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20
mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more
patients in Stage 1 have an objective response after 12 weeks of treatment, the study will
proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined
population of 47. Overall, objective responses must be observed in 10 patients for the study
to be declared a success.


Phase

Phase 2


Funding Agency/Sponsor

Industrial


Disease

Breast Cancer


Enrollment Eligibility

Inclusion Criteria:
1. The patient (or legally acceptable representative if applicable) provides written
informed consent for the trial.
2. Be 18 years of age on day of signing informed consent.
3. Have historically confirmed histological diagnosis of metastatic ER/PR+/HER2(-)
subtype breast cancer
1. HR+: Positive for estrogen receptor and/or progesterone receptor staining,
indicated by ≥1% immunoreactive tumor nuclei
2. HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of
tumor cells (IHC score of 0 to 1+) or negative by dual probe in situ
hybridization assay
4. Have peripheral blood levels of IgG anti-β-glucan antibody (ABA) of greater than, or
equal to 20 mcg/mL as determined by an ELISA test within 90 days prior to start of
study treatment.
5. Must have progressed on at least one hormone therapy (AI or SERD) + CDK 4/6 inhibitor
(and alpelisib if PIK3CA mutated) and up to two lines of prior chemotherapy (i.e.,
capecitabine, taxanes). (Patient may have progressed after any number of hormone
therapies alone or combined with small molecule inhibitors, i.e., mTOR, PIK3CA, CDK
4/6, etc.)
6. Have documented objective radiographic or clinical disease progression after treatment
with estrogen-targeted therapies with at least one CDK4/6 inhibitor.
7. Be willing to provide an archival tissue sample and undergo one on-treatment core or
excisional biopsy of a tumor lesion not previously irradiated (Formalin-fixed,
paraffin embedded [FFPE]tissue blocks are preferred to slides).
8. Have at least one radiologically measurable lesion as per RECIST v1.1 defined as a
lesion that is at least 10 mm in longest diameter imaged by CT scan or MRI and
obtained by imaging within 28 days prior to registration. Lesions situated in a
previously irradiated area are considered measurable if progression has been
demonstrated in such lesions.
a. Note: Patients with bone only metastases (BOM) are not eligible, except if such
lesions have a distinct, associated soft tissue component that is measurable as per
RECIST 1.1.
9. Have resolution of all previous treatment-related toxicities to Grade 1 severity or
lower, except for stable sensory neuropathy (less than or equal to Grade 2) and
alopecia. If the patient received major surgery or radiation therapy of > 30 Gy, must
have recovered from the toxicity and/or complications from the intervention.
10. Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
11. Have life expectancy of 3 months or greater as determined by the treating physician.
12. Have a negative PCR test at screening for SARS-COV-2 RNA.
13. Have adequate organ function (all screening labs should be performed within 10 days
prior to treatment initiation):
14. Female patients of childbearing potential must have a negative urine or serum
pregnancy within 72 hours prior to receiving the first dose of study medication. If
the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
will be required.
15. A female patient is eligible to participate if she is not pregnant, not breastfeeding,
and at least one of the following conditions applies
1. Not a woman of childbearing potential (WOCBP)
2. A WOCBP who agrees to follow contraceptive guidance during the treatment period
and for at least 120 days after the last dose of study treatment.
16. Be willing and have the ability to comply with scheduled visits (including
geographical proximity), treatment plans, laboratory tests, and other study
procedures.
Exclusion Criteria:
The patient must be excluded from participating in the trial if the patient:
1. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX 40, CD137).
2. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients
must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted
for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
3. Has received prior systemic anti-cancer therapy including investigational agents
within 4 weeks to Study Day 1 (or within 2 weeks for kinase inhibitors or other short
half-life drugs), or within 5 half-lives for a prior investigational drug and two
weeks from use of an investigational device.
1. Note: Patients must have recovered from all AEs due to previous therapies to
≤Grade 1 or baseline. Patients with ≤Grade 2 neuropathy may be eligible. Patients
with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement
may be eligible.
2. Note: If the patient had major surgery, the patient must have recovered
adequately from the procedure and/or any complications from the surgery prior to
starting study intervention.
4. Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.
c. Note: Patients who have entered the follow-up phase of an investigational study may
participate as long as it has been 4 weeks after the last dose of the previous
investigational agent.
5. Has received a live or live-attenuated vaccine within 30 days prior to the first dose
of study intervention. Note:
Administration of killed vaccines are allowed.
6. Has had an allogeneic tissue/solid organ transplant.
7. Has received transfusion of blood products (including platelets or red blood cells) or
administration of colony stimulating factors (including G-CSF, GM-CSF, or recombinant
erythropoietin) within 4 weeks prior to Study Day 1.
8. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study drug.
9. Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years.
a. Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of
the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that
have undergone potentially curative therapy are not excluded.
10. Has known active CNS metastases and/or carcinomatous meningitis. Patients with
previously treated brain metastases may participate provided they are radiologically
stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging
(note that the repeat imaging should be performed during study screening), clinically
stable and without requirement of steroid treatment for at least 14 days prior to
first dose of study treatment.
11. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
12. Had previous exposure to Imprime PGG.
13. Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a form
of systemic treatment and is allowed.
14. Has a history of (non-infectious) pneumonitis / interstitial lung disease that
required steroids or has current pneumonitis/ interstitial lung disease.
15. Has an active infection requiring systemic therapy.
16. Has known history of active tuberculosis.
17. Has a known history of HIV infection. No HIV testing is required unless mandated by
local health authority.
18. Has a known history of Hepatitis B (defined as HBsAg reactive) or known active
Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
a. Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by a
local health authority.
19. Has a clinically significant cardiovascular disease such as unstable angina,
myocardial infarction, or acute coronary syndrome within ≤ 6 months prior to start of
study treatment, symptomatic or uncontrolled arrhythmia, congestive heart failure, or
any Class 3 or 4 cardiac disease as defined by the New York Heart Association
Functional Classification.
20. Has any other concurrent severe and/or uncontrolled medical condition that would, in
the investigator's judgment, contraindicate the patient in the clinical study.
21. Has a known psychiatric or substance abuse disorder that would interfere with the
patient's ability to cooperate with the requirements of the study.
22. A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment.
If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
test will be required.
23. Is breast feeding or expecting to conceive children within the projected duration of
the trial, starting with the prescreening or screening visit through 120 days after
the last dose of trial treatment.
24. Is a first-degree relative of the investigator, study staff or study sponsor.


Contact Information

Phone Number 305-243-2647
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.